Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes

Diabetes

Volumn 65, Issue 12, 2016, Pages 3765-3775

  Haller, Michael J ^a   Gitelman, Stephen E ^b   Gottlieb, Peter A ^c   Michels, Aaron W ^c   Perry, Daniel J ^a   Schultz, Andrew R ^a   Hulme, Maigan A ^d   Shuster, Jonathan J ^e   Zou, Baiming ^e   Wasserfall, Clive H ^a   Posgai, Amanda L ^a   Mathews, Clayton E ^a   Brusko, Todd M ^a   Atkinson, Mark A ^a   Schatz, Desmond A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d J Crayton Pruitt Family Department of Biomedical Engineering   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AUTOANTIBODY; C PEPTIDE; CD16 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; COTRIMOXAZOLE; HEMOGLOBIN A1C; HLA DR ANTIGEN; INSULIN; METHYLPREDNISOLONE; PARACETAMOL; PEGFILGRASTIM; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; PROTEIN HELIOS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CXCR3 PROTEIN, HUMAN; FC RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOLOGIC FACTOR; LYMPHOCYTE ANTIBODY; MACROGOL DERIVATIVE; PEGYLATED GRANULOCYTE COLONY-STIMULATING FACTOR; RECOMBINANT PROTEIN;

ADULT; ANTIBODY TITER; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; EFFECTOR CELL; ENDOCRINE PANCREAS FUNCTION TEST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; IMMUNOPHENOTYPING; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MEMORY T LYMPHOCYTE; METABOLIC PARAMETERS; METABOLISM; MIXED MEAL TOLERANCE TEST; MONOCYTE; MULTICENTER STUDY; NATURAL KILLER CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SIDE EFFECT; SINGLE BLIND PROCEDURE; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; ADOLESCENT; CHILD; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD56; ANTILYMPHOCYTE SERUM; AREA UNDER CURVE; C-PEPTIDE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MONOCYTES; POLYETHYLENE GLYCOLS; RECEPTORS, CXCR3; RECEPTORS, IGG; RECOMBINANT PROTEINS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 85000502393     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0823     Document Type: Article

References (25)

1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014; 383:69-82.
2. Staeva TP, Chatenoud L, Insel R, Atkinson MA. Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 2013;62:9-17.
3. Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol 2013;9:92-103.
4. Ludvigsson J. Combination therapy for preservation of beta cell function in type 1 diabetes: new attitudes and strategies are needed! Immunol Lett 2014; 159:30-35.
5. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007;297:1568-1576.
6. Snarski E, Milczarczyk A, Torosian T, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant 2011;46:562-566.
7. Li L, Shen S, Ouyang J, et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves b-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab 2012;97:1729-1736.
8. D'Addio F, Valderrama Vasquez A, Ben Nasr M, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: A multicenter analysis. Diabetes 2014;63:3041-3046.
9. Gitelman SE, Gottlieb PA, Felner EI, et al.; ITN START Study Team. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia 2016;59:1153-1161.
10. Gitelman SE, Gottlieb PA, Rigby MR, et al.; START Study Team. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2013;1:306-316.
11. Haller MJ, Atkinson MA, Wasserfall CH, et al. Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes. Clin Exp Immunol 2016;183:350-357.
12. Haller MJ, Gitelman SE, Gottlieb PA, et al. Anti-Thymocyte globulin/G-CSF treatment preserves b cell function in patients with established type 1 diabetes. J Clin Invest 2015;125:448-455.
13. Schlosser M, Mueller PW, Törn C, Bonifacio E, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: Evaluation of assays for insulin autoantibodies. Diabetologia 2010;53:2611-2620.
14. Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: Evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008;51:846-852.
15. Lampasona V, Schlosser M, Mueller PW, et al. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 2011;57:1693-1702.
16. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 2012;12:191-200.
17. He J, Tsai LM, Leong YA, et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5? CD4? T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 2013;39:770-781.
18. Locci M, Havenar-Daughton C, Landais E, et al.; International AIDS Vaccine Initiative Protocol C Principal Investigators. Human circulating PD-1+CXCR3- CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013;39:758-769.
19. Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes-considerations for attempts to prevent and reverse the disease. Diabetes Care 2015;38:979-988.
20. Cantú-Rodríguez OG, Lavalle-González F, Herrera-Rojas MA, et al. Longterm insulin independence in type 1 diabetes mellitus using a simplified autologous stem cell transplant. J Clin Endocrinol Metab 2016;101:2141-2148.
21. Ehlers MR. Immune interventions to preserve b cell function in type 1 diabetes. J Investig Med 2016;64:7-13.
22. Buckner JH, Nepom GT. Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes. J Autoimmun 2016;71:44-50.
23. Campbell-Thompson M, Fu A, Kaddis JS, et al. Insulitis and b-cell mass in the natural history of type 1 diabetes. Diabetes 2016;65:719-731.
24. Xue S, Posgai A, Wasserfall C, et al. Combination therapy reverses hyperglycemia in NOD mice with established type 1 diabetes. Diabetes 2015;64: 3873-3884.
25. Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 2009;52:1680- 1682.